Table 1 Demographic and clinical characteristics at baseline (intent-to-treat population, N=173)

From: Epoetin alfa in platinum-treated ovarian cancer patients: results of a multinational, multicentre, randomised trial

Characteristic

Epoetin alfa ( n= 114)

Best standard treatment ( n= 59)

Mean age, year (±s.d.)

59.1 (±10.6)

60.3 (±11.2)

 Range

35.0–87.0

30.0–79.0

Mean Hb level±s.d. (g dl−1)

10.75±0.94

10.66±0.83

ECOG performance score (n, %)a

 0

56 (49.1)

27 (45.8)

 1

47 (41.2)

29 (49.2)

 2

11 (9.6)

3 (5.1)

 3

0 (0.0)

0 (0.0)

 4

0 (0.0)

0 (0.0)

Tumour stage, n (%)

 I

12 (10.5)

10 (16.9)

 II

13 (11.4)

3 (5.1)

 III

58 (50.9)

32 (54.2)

 IV

28 (24.6)

13 (22.0)

 Unknown

3 (2.6)

1 (1.7)

Metastatic disease, n (%)

 Unknown

1 (0.9)

0 (0.0)

 None

27 (23.7)

13 (22.0)

 Abdominal

66 (57.9)

32 (54.2)

 Liver

12 (10.5)

6 (10.2)

 Lymphatic

12 (10.5)

6 (10.2)

 Lung

7 (6.1)

5 (8.5)

 Other type

34 (29.8)

17 (28.8)

Previous surgery, n (%)

94 (82.5)

49 (83.1)

Type of chemotherapy, n (%)

 Carboplatin

75 (65.8)

40 (67.8)

 Carboplatin + paclitaxel

29 (25.4)

14 (23.7)

 Cisplatin

10 (8.8)

5 (8.5)

  1. a0=able to carry out normal activities, 1=restricted physical activity/ambulatory/light work, 2=ambulatory/capable of all self-care/unable to work, 3=capable of only limited self-care, 4=completely disabled.
Back to article page